SurModics, Inc. (SRDX)

The past six months have seen several significant events impacting Surmodics, Inc.'s stock price. On May 29, 2024, Surmodics announced a definitive agreement to be acquired by an affiliate of GTCR LLC, but the U.S. Federal Trade Commission (FTC) issued a Second Request for additional information regarding the merger and later moved to block the proposed acquisition, causing SRDX shares to fall. Amid a pre-trial hearing in the FTC's lawsuit on July 25, 2025, Surmodics' stock rose 12% as the company proposed a divestiture in an effort to appease the FTC. On October 1, 2024, Surmodics announced the receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ XL Thrombectomy System, and on October 27, 2025, the company announced that sex-specific data from the PROWL Registry would be presented at the TCT Conference on October 28. Surmodics reported its first quarter of fiscal year 2025 financial results on January 30, 2025, showing a decrease in total revenue, a GAAP net loss, and a decrease in Adjusted EBITDA, but expressed confidence in its financial health, highlighting strong sales performance in thrombectomy platforms and medical device coatings. The company also reported a Q3 earnings beat with a narrower loss and revenue topping estimates, despite lower SurVeil DCB sales.

The provided information does not contain explicit details regarding demand seasonality for Surmodics, Inc.'s products and services.

Surmodics, Inc. is a provider of surface modification technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company operates within the Health Technology sector, specifically in the Medical Specialties and Medical/Dental Instruments industries. Surmodics' mission is to enhance the treatment and detection of diseases by offering solutions to complex medical device and diagnostic challenges. The company's major products and technologies fall into two primary segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment includes surface modification coating technologies and drug-delivery coating technologies. Key products include the Pounce™ Thrombectomy Platform and Serene™ hydrophilic coatings. The In Vitro Diagnostics (IVD) segment provides component products and technologies for diagnostic test kits and biomedical research applications, including protein stabilization reagents, substrates, antigens, and surface coatings.

Surmodics, Inc. is headquartered in Eden Prairie, Minnesota, USA. The company's technologies and products are utilized by medical device manufacturers and in diagnostic test kits globally, implying an international market reach.

Surmodics' brand reputation over the past year has been influenced by a mix of positive developments and significant challenges. The FDA 510(k) clearance for its Pounce™ XL Thrombectomy System and the successful early clinical use of the Pounce XL Thrombectomy System are positive events. The launch of Serene® Single-Coat (SC) solutions also contributes positively to its standing. However, the proposed acquisition by GTCR and the subsequent legal challenge by the FTC have introduced uncertainty and potential reputational risks.

The ownership structure of Surmodics, Inc. (SRDX) is distributed among various investor types. Insiders hold 31.14% of the stock, Mutual Funds own 6.63%, Other Institutional Investors account for 23.24%, and Public Companies and Individual Investors collectively hold 30.74%.